Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Completed · Phase 1

Conditions studied: Prostate Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining estramustine and paclitaxel in treating patients who have prostate cancer that has not responded to hormone therapy.

Key facts

Study ID

NCT00005048

Run by

NYU Langone Health

Starts

1997-04-01

Last updated by the study team

2012-11-09

Who can join

Age: any. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Kaplan Cancer Center — New York, New York, United States
• Mount Sinai Medical Center, NY — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.